Delgocitinib is a Janus kinase (JAK) inhibitor being developed for the treatment of atopic dermatitis. United States Patent US10822354B2, titled "COMPOSITIONS AND METHODS FOR TREATING IMMUNE AND INFLAMMATORY DISEASES," describes compositions and methods for treating immune and inflammatory diseases, including atopic dermatitis, using delgocitinib [1].
What is Delgocitinib Used For?
Delgocitinib is being investigated for its potential to treat immune and inflammatory conditions. Primarily, it is undergoing development for atopic dermatitis, a chronic inflammatory skin disease. Clinical trials are exploring its efficacy and safety in patients with moderate to severe atopic dermatitis [1].
How Does Delgocitinib Work?
Delgocitinib functions as a Janus kinase (JAK) inhibitor. JAKs are enzymes that play a crucial role in signaling pathways involved in inflammation and immune responses. By inhibiting these enzymes, delgocitinib can modulate the immune system and reduce inflammation, thereby alleviating symptoms associated with conditions like atopic dermatitis [1].
When Does Patent US10822354B2 Expire?
Information regarding the specific expiration date of United States Patent US10822354B2 is not provided in the context of this query. Patent expiration dates are crucial for determining when generic versions of a drug can be introduced to the market. For detailed patent information, resources like DrugPatentWatch.com can be consulted [2].
What Other Patents Cover Delgocitinib?
While US10822354B2 specifically addresses compositions and methods for treating immune and inflammatory diseases, other patents may exist that cover different aspects of delgocitinib, such as its synthesis, formulation, or specific therapeutic uses. Comprehensive patent searches are necessary to identify all relevant intellectual property protecting the drug [2].
Who is Developing Delgocitinib?
The development of delgocitinib is being pursued by various pharmaceutical companies. In Japan, Torii Pharmaceutical Co., Ltd. markets delgocitinib under the brand name Spevigo for atopic dermatitis [3]. AbbVie acquired the global rights to delgocitinib from Vitae Pharmaceuticals in 2016 [4].
How Does Delgocitinib Compare to Other Atopic Dermatitis Treatments?
Delgocitinib is a topical JAK inhibitor. Other treatments for atopic dermatitis include topical corticosteroids, topical calcineurin inhibitors, and systemic therapies such as oral JAK inhibitors and biologics. Delgocitinib's mechanism of action, targeting specific inflammatory pathways, differentiates it from some other treatment classes. Its efficacy and safety profile are being evaluated against existing standards of care [1].
What are the Potential Risks and Side Effects of Delgocitinib?
As with any medication, delgocitinib may have potential risks and side effects. While specific details from US10822354B2 are not elaborated upon, JAK inhibitors as a class can be associated with side effects such as infections, blood count changes, and potential cardiovascular events. Ongoing clinical trials and post-market surveillance monitor these aspects closely. Patients should discuss potential risks with their healthcare providers [1].
Where Can I Find More Information on Delgocitinib Patents?
For comprehensive and up-to-date information on delgocitinib patents, including US10822354B2, resources like DrugPatentWatch.com offer detailed patent landscapes, expiration dates, and litigation information. These platforms are valuable for researchers, industry professionals, and patients seeking to understand the intellectual property surrounding pharmaceutical products [2].
---
Sources:
[1] https://patents.google.com/patent/US10822354B2
[2] https://www.drugpatentwatch.com/
[3] https://www.torii.co.jp/en/news/2021/0316_01.pdf
[4] https://news.abbvie.com/news/press-releases/abbvie-acquires-vitae-pharmaceuticals.html